Mary Ann Liebert, Inc. has announced that Dr. Wai Hong (Kevin) Lo has been named the new Editor-in-Chief of the journal ASSAY and Drug Development Technologies. Dr. Lo succeeds Dr. Bruce Melancon in this prestigious role.
ASSAY and Drug Development Technologies is a peer-reviewed journal that provides cutting-edge research and innovative methodologies in early-stage screening, enabling key advancements in drug discovery and development. The journal features original research papers, technology reviews, and reports on novel methodologies that are instrumental in the progression of therapeutics and drug development platforms.
Dr. Lo, an Associate Professor at the University of Connecticut Health Center, brings over 20 years of experience as a biotechnology researcher and translational scientist. His expertise spans tissue regenerative engineering, biochemistry, biomaterials development, and drug discovery. His research has been consistently funded by federal agencies, including the National Institutes of Health.
Dr. Lo also has a distinguished editorial background, serving as the founding Deputy Editor of the Journal of Racial and Ethnic Health Disparities and Associate Editor for PLoS ONE and Frontiers in Bioengineering and Biotechnology. He is a member of the editorial boards of several notable journals, including Scientific Reports and Regenerative Engineering and Translational Medicine.
With his vast expertise, Dr. Lo is set to lead ASSAY and Drug Development Technologies in continuing its mission of delivering impactful scientific insights to the drug development community.
Click here to read the original press release.
